Context: Medullary thyroid carcinoma ( MTC) metastasizes early in its clinical course. No effective systemic therapy is available. Generally ( somatic or germline), mutations in the rearranged during transfection gene are considered essential in the pathogenesis of MTC.Objective: We investigated imatinib, a tyrosine kinase inhibitor, as a potential treatment in patients with disseminated MTC.Design: A phase II study was initiated using 600 mg imatinib daily with a possible dose increase to 800 mg in case of progression. Standard Response Evaluation Criteria in Solid Tumors were used using computed tomography or magnetic resonance imaging every 2 months.Results: There were 15 patients with disseminated MTC treated for up to 12 months. No obj...
BACKGROUND: This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a recepto...
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thy...
Background: Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC,...
Context: Medullary thyroid carcinoma ( MTC) metastasizes early in its clinical course. No effective ...
Background: Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC)...
Context: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer tha...
PURPOSE: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET),...
Introduction: Until recently, no therapeutic options were available for the treatment of advanced me...
PURPOSE: This phase II study investigated the efficacy and tolerability of motesanib, an investigat...
"Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (...
Context: Thyroid cancer is usually cured by timely thyroidectomy, however the treatment of patients ...
Medullary thyroid carcinoma (MTC) is a rare tumor arising from neural crest-derived parafollicular C...
Purpose: Patients with advanced radioactive iodine resistant differentiated (MDTC) or medullary (MMT...
BACKGROUND: This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a recepto...
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thy...
Background: Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC,...
Context: Medullary thyroid carcinoma ( MTC) metastasizes early in its clinical course. No effective ...
Background: Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC)...
Context: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer tha...
PURPOSE: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET),...
Introduction: Until recently, no therapeutic options were available for the treatment of advanced me...
PURPOSE: This phase II study investigated the efficacy and tolerability of motesanib, an investigat...
"Context: To date no efficacious treatments are available for advanced medullary thyroid carcinoma (...
Context: Thyroid cancer is usually cured by timely thyroidectomy, however the treatment of patients ...
Medullary thyroid carcinoma (MTC) is a rare tumor arising from neural crest-derived parafollicular C...
Purpose: Patients with advanced radioactive iodine resistant differentiated (MDTC) or medullary (MMT...
BACKGROUND: This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a recepto...
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thy...
Background: Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC,...